Podcasts about patient outcomes

  • 256PODCASTS
  • 918EPISODES
  • 37mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Nov 29, 2022LATEST

POPULARITY

20152016201720182019202020212022

Categories



Best podcasts about patient outcomes

Show all podcasts related to patient outcomes

Latest podcast episodes about patient outcomes

OffScrip with Matthew Zachary
When The Software Engineer Becomes The Patient Advocate

OffScrip with Matthew Zachary

Play Episode Listen Later Nov 29, 2022 35:33


An economist turned diagnostician, Mette Dhyrberg took matters into her own hands, hacked her own health, and soon began helping others do the same. Mette is the Founder and CEO of MyMee, a digital health platform that identifies the unique dietary and environmental factors that drive mild, moderate, or severe symptoms for people living with chronic conditions and rare disease. So without further ado, we present the tale of when the software engineer becomes the accidental patient advocate. Enjoy the show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

OffScrip with Matthew Zachary
[BONUS] The Gratitude Show with Koby and Hannah

OffScrip with Matthew Zachary

Play Episode Listen Later Nov 24, 2022 9:19


While America has a complicated history worth acknowledging, Thanksgiving, at least for my family and me, is a holiday dedicated to gratitude and tolerance. On today's special bonus minisode, I'm joined once again by my miracle twins, Koby and Hannah, to talk about what we are thankful for this year, especially through the lens of what's going on inside the minds of 12-year 7th graders in NYC these days. Thank you so much to my loyal listeners for tuning in each week and supporting our shared mission. Enjoy the show, and Happy Thanksgiving.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

OffScrip with Matthew Zachary
Musical Theater Nerd Patient Advocates Unite: Jennifer "Jay" Palumbo

OffScrip with Matthew Zachary

Play Episode Listen Later Nov 22, 2022 36:07


On today's quirky show, I welcome Jen Palumbo, an epic human Energizer Bunny who takes a licking and keeps on ticking. Jen is a freelance writer, Forbes contributor, and women's health advocate, specifically for reproductive rights. In a spirited coincidence, it turns out we both went to the same college at the same time, were both Theater people, and have dozens of friends in common. We are ships in the night for sure. As fellow parents of IVF children, we bonded over the current state of the state. And as fellow Binghamton graduates, we bonded over Wegmans, being Theater nerds, and 1990s dorm life in the southern tier. Jen is a true Long Island: loud and proud. Let the hilarity, dark humor, and GenX Therapy begin. Enjoy the show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

OffScrip with Matthew Zachary
Introducing the "Before We Die" Podcast from OffScrip Health

OffScrip with Matthew Zachary

Play Episode Listen Later Nov 17, 2022 34:41


Today I am joined by Ariel Nachmann and Joey Brenneman, co-producers from the offscrip network and also the hype team behind the all-new Before We Die podcast from OffScrip Health! Although the title sounds a bit macabre, this show is all about saving lives with emerging technology. We're here to fuel your anger and get you riled up to demand access to new medical technologies that are often faster, better, and cheaper than the standard of care. The process of getting these products to patients must be accelerated Before We Die! This “clip show” gives you a peek into this full season and introduces you to the Before We Die creators and panel of experts, Sandra Miller, John MacMahon, and Craig Ullman. Subscribe to OffScrip Health's Before We Die on Apple Podcasts, Spotify, or wherever you enjoy listening to your podcasts.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Restless Ones
Where Data & Response Times Matter Most – How 5G is making a difference in patient outcomes: Ray Bajaj, Chief Technology, Cardinal Health

The Restless Ones

Play Episode Listen Later Nov 15, 2022 33:28


Technology continues to change every aspect of the healthcare industry. From the treatments, devices, and medicines available to patients, to the supply chain and distribution methods designed to provide access for all. The advent of 5G has had an impact well beyond telemedicine. Connectivity has touched all aspects of the medical field, from the computing power needed for drug research, to supply chain management, to the data made readily available through smart devices. Organizations such as Cardinal Health are seizing the opportunity to use these technologies, changing the ways healthcare is delivered to patients. For this episode of The Restless Ones, I had the opportunity to sit with Ray Bajaj, Chief Technology of Cardinal Health, a multi-faceted company focused on improving access, affordability, and adherence across the industry. Ray sees the formula to success as the ability to advance the speed and slope of technology while concurrently changing the culture of his organization. From connected devices such as neonatal machines, and other critical equipment, to the latest digital therapeutic techniques, helping “unbundle the hospital” and create what will become the future of pharmacy care, Ray's team is pushing the limits of technologies “to make a difference, in an industry that makes a difference.See omnystudio.com/listener for privacy information.

OffScrip with Matthew Zachary
SportsCancer Recap: AVBCC 2022 Conference

OffScrip with Matthew Zachary

Play Episode Listen Later Nov 15, 2022 15:21


In today's bonus episode of Out of Patients, I welcome back to the studio returning champion Gail Zahtz. We recently attended a super wonky, jargon-filled trade show, and we're here to break it all down for you—the listener— in ordinary human lay speak. The Association for Value-Based Cancer Care (AVBCC) is a behind-the-scenes organization deep in the subbasement of healthcare. Their purpose is to ensure that the "right patients" get prescribed the "right medicine" at the "right time," hopefully with minimal drama, while avoiding anyone going bankrupt. That's the gist. So strap in as we attempt to de-wonkify a bunch of acronyms in corporate bingo land, and maybe—we hope— you learn something along the way that can make your healthcare experiences suck a little less. Enjoy the show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Closing the Gap with Denise Cooper
EDI Expert Joann Wortham on improving patient outcomes through building trust

Closing the Gap with Denise Cooper

Play Episode Listen Later Nov 10, 2022 40:51


How does the healthcare industry address issues of equity, diversity, and inclusion? Healthcare systems are run on data. This data can include anything from number of falls, number of infections, to how long it takes patients to enter and leave healthcare locations. This data also shows us that the number of wrong site surgeries go up when people don't feel psychologically safe to speak up. There is a direct correlation between the level of trust and safety that people feel at work, and the lived experience of patient outcomes. In this week's episode, EDI expert, Joann Wortham tells us about her experiences in helping healthcare executives address discrimination and inequity in their field. If you've been wondering how you can move the needle and influence patient outcomes for the better, this is the episode for you.THE FINER DETAILS OF THIS SHOWHow did you decide to step out of a lucrative career into the field of EDI (equity, diversity, and inclusion)? [02:26]How can an administration better understand the experiences of women and minorities in the healthcare system?[15:38]How do you inspire leaders in the healthcare industry to embrace EDI?[23:31]KEEP UP WITH JOANN WORTHAMFollow Joann Wortham on LinkedinEDI Is the New Black: Lead the Market with Diverse TeamsEPISODE RESOURCESJoin the Remarkable Leadership Lessons Community NowVisit the Remarkable Leadership Lessons SiteGot questions? Send them hereInterested in being a guest? Schedule an introduction call!Subscribe on Apple Podcasts, Spotify, or Google Podcasts, and leave us a rating or reviewGUEST BIOJoann Wortham is a seasoned international thought leader who uses insight from lived experiences along with her background in education, healthcare, business, and risk management to create novel approaches to today's most critical workplace concerns. With over twenty years of experience, as well as a Master of Science in nursing education and a Juris Doctorate, Ms. Wortham has presented and consulted for such prestigious groups as the Institute of Healthcare Improvement (IHI) and Yale Health. She was also a consultant and contributor to the American Society of Risk Management's (ASHRM) Human Capital Playbook. Her current book is entitled EDI is the New Black.

OffScrip with Matthew Zachary
The Cancer Mavericks Series Finale: If History Teaches Us Anything

OffScrip with Matthew Zachary

Play Episode Listen Later Nov 10, 2022 18:55


Welcome to the series finale of The Cancer Mavericks. In this final episode, we reflect on the first seven episodes through the lens of history and progress with a series of insightful conversations featuring some of healthcare's most influential and visionary voices across the past four decades. If history is a teacher, we have learned that change can happen, albeit slowly. But it is only when the people stand up, organize and activate their voices demanding change, that the culture will shift, the institutions will pivot, and the very system itself will be forced by the will of the citizens to bend towards the arc of justice. Thank you for joining us for this groundbreaking series. If you like this series, please leave a review and a rating on your favorite podcast app. To learn more about The Cancer Mavericks, visit https://CancerMavericks.com. To learn more about OffScrip Health, visit https://OffScrip.com.FEATURED VOICESGil BasheChair Global Health and Purpose, FINN PartnersJohn D. Carpten, Ph.D.President's Cancer Panel (Emeritus)Director, Institute of Translational GenomicsKeck School of Medicine at USCDeanna DarlingtonPresident at Links2EquityKenny KaneYoung Adult Cancer Advocacy PioneerCo-Founder/CEO, Stupid Cancer (Former)Margaret LawsPresident and CEO, Hope LabLisa C. Richardson, MD, MPHDivision Director, Cancer Prevention and Control at The CDCCatharine Young, Ph.D.Assistant Director of Cancer Moonshot Engagement and PolicyThe White HouseSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

OffScrip with Matthew Zachary
How to be Sick: The Just Diagnosed Guides

OffScrip with Matthew Zachary

Play Episode Listen Later Nov 8, 2022 36:46


Today, I proudly welcome my cancer survivor comrade at arms, Jen Singer. Jen's got the trifecta of "shit happens," having survived cancer, heart failure, and "COVID Classic" back in February of 2020 when no one had any idea what the hell was going on. She is the creator of "How To Be Sick," patient-friendly ebooks called "The Just Diagnosed Guides" to provide the newly diagnosed with the information they really need to know now. Because who actually knows what they need to know when they never knew they needed to know it? She's an outspoken professional despiser of Dr. Google, which I think we could all agree is the worst place to go when bad things happen. And as fellow cancer survivors, we bonded over how the hell we're both still alive all these years later through humor, empathy, and virtual cocktails. Enjoy the show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

OffScrip with Matthew Zachary
White House Cancer Moonshot Coordinator Danielle Carnival, Ph.D.

OffScrip with Matthew Zachary

Play Episode Listen Later Nov 3, 2022 40:00


I was privileged to welcome Dr. Danielle Carnival, White House Cancer Moonshot Coordinator, to the studio. We talked about the President's priorities, principal directives, and legislative strategies, as well as what Americans can look forward to in the coming months and years through this ambitious and transformational National initiative. Carnival, who has a Ph.D. in neuroscience, served as chief of staff and senior policy director for the 2016-2017 White House Cancer Moonshot Task Force. Subsequently, she served as vice president of the Biden Cancer Initiative. She's also a friend of Wegman's. So there's that, too. To learn more about the Whitehouse Cancer Moonshot initiative, visit https://www.whitehouse.gov/cancermoonshot. Enjoy the show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
James F. Howard Jr., MD - A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Nov 3, 2022 67:29


Go online to PeerView.com/VZG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Traditionally used treatments for gMG are broadly immunosuppressive, do not target pathogenic immunoglobulin G (IgG) autoantibodies, and provide insufficient symptom relief with significant side effects. Fortunately, advances in the understanding of gMG pathogenesis are leading to the development of new treatment options, including neonatal Fc receptor (FcRn) modulators such as the recently approved efgartigimod, and rozanolixizumab, which recently completed phase 3 trials. As with all new and emerging therapeutics, it is important for clinicians to remain abreast of the latest data. At a recent live event, a multidisciplinary panel of experts compared the safety, efficacy, and tolerability of new treatment options with traditional therapies for gMG. Audience members received expert advice from the perspective of a neurologist, pharmacist, and infusion nurse, with the goal of providing their patients with individualized care through FcRn modulation therapy. Upon completion of this activity, participants should be better able to: Compare safety, efficacy, and tolerability of new treatment options with traditional therapies for generalized myasthenia gravis (gMG); Apply an understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions; and Implement a safe administration protocol for the use of FcRn-modulating therapy that includes infusion procedures, premedications, vaccinations, and treatment cycle timing.

OffScrip with Matthew Zachary
From Pinterest to Glioblastoma Research

OffScrip with Matthew Zachary

Play Episode Listen Later Nov 1, 2022 35:51


Today on the show, I welcome Vikram Bhaskaran, and Dr. Rohan Ramakrishna (Chief of Neurological Surgery at New York Presbyterian) live in-studio to talk about Roon, their intriguing new cancer navigation platform for patients and caregivers. Roon is personal to Vikram as his whole career shifted from Pinterest executive to caring for his Father when he was diagnosed with ALS. Roon claims to be "the most supportive place online for people navigating complex health conditions, starting with Glioblastoma." so we power-test how that holds up against unmet patient needs. Rohan is only the second neurosurgeon I've had on the show, so, as a brain cancer survivor, I naturally asked him all sorts of pointed questions like, "What's it like to touch someone's brain?" These guys are the real deal with core compassion for empathy in medicine and helping patients in need access what they never knew they needed. Enjoy the show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Naval Daver, MD, Amir T. Fathi, MD - The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 28, 2022 64:25


Go online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView's latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols. Upon completion of this activity, participants should be better able to: Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings; Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features; Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Scott T. Tagawa, MD, MS, FACP - Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Oct 28, 2022 40:12


Go online to PeerView.com/VRE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Metastatic urothelial carcinoma (UC) is a devastating illness with limited treatment options, especially for patients who have been previously treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. The activity also features a patient and his caregiver's perspective on their first-hand experience with the treatment strategies and his journey. These experts review the latest data and ongoing research on platinum-based chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants should be better able to: Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations; Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care; Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Naval Daver, MD, Amir T. Fathi, MD - The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 28, 2022 64:36


Go online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView's latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols. Upon completion of this activity, participants should be better able to: Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings; Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features; Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Scott T. Tagawa, MD, MS, FACP - Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 28, 2022 40:00


Go online to PeerView.com/VRE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Metastatic urothelial carcinoma (UC) is a devastating illness with limited treatment options, especially for patients who have been previously treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. The activity also features a patient and his caregiver's perspective on their first-hand experience with the treatment strategies and his journey. These experts review the latest data and ongoing research on platinum-based chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants should be better able to: Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations; Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care; Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination

OffScrip with Matthew Zachary
[THROWBACK] Pay the Patients: It's Time to Compen$ate Patients for Their Experience

OffScrip with Matthew Zachary

Play Episode Listen Later Oct 27, 2022 29:38


Today we're dropping a very special throwback to an early episode of Out of Patients.Too often, patients are blatantly taken advantage of by Industry who profit off of our stories and our experience dealing with a disease we didn't ask to have. If our experience is so critical to Industry's bottom line, there should exist fundamental compensation standards under which which they operate. Period.Matthew Zachary welcomes OffScrip Media Senior Producers Andrew MacDowell (Co-Founder and COO,) Jen Horonjeff (Founder/CEO of Savvy Coop) and Sandy Vassos (Nonprofit Executive and OffScrip Media Advisor for Strategic Relationships)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

OffScrip with Matthew Zachary
Getting Endlessly Misdiagnosed Is Fabulous!

OffScrip with Matthew Zachary

Play Episode Listen Later Oct 25, 2022 33:37


The amazing Victoria Fenton joins me today from across the pond in England to share one of the greatest British accents I've ever welcomed to the program. Well, that and the fabulous feeling when you know something is wrong with your body, and no medical professional will take you seriously while regurgitating back to you that it's all in your head. Victoria was misdiagnosed for over a decade as a teenager while suffering from all sorts of life-threatening symptoms. Consistently greeted with "You have mental health issues. Get over it." she was finally diagnosed with Ehlers-Danlos Syndrome (EDS), a group of hereditary disorders of connective tissue. She realized that when you have no control over something, it helps you take control of it. She chose to immerse herself in natural language processing and cognitive behavioral therapy. She soon realized the obvious: Our minds and our bodies can control the way we interact with the universe around us. Not heal. Not sure. But help manage the way we deal with stressors. Enjoy the show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Boomer Living Tv - Podcast For Baby Boomers, Their Families & Professionals In Senior Living
Johannes Boshkow - Behavioral Science: The Key to Better Patient Outcomes for Baby Boomers

Boomer Living Tv - Podcast For Baby Boomers, Their Families & Professionals In Senior Living

Play Episode Listen Later Oct 23, 2022 55:48


Imagine for a moment that you have been diagnosed with a chronic illness. Perhaps it's diabetes or heart disease. You know that if you don't take care of yourself, the consequences could be severe. So you diligently follow your treatment plan, checking your blood sugar levels or taking your medication every day without fail.But then one day, life gets in the way. You miss a dose of medication, or you forget to test your blood sugar. It seems like no big deal at the time, but soon enough, you start to slip into old habits. Before long, you're back to square one, struggling to manage your illness.And that's where behavioral science comes in. Behavioral science is the study of understanding human behavior. It helps us understand how we can change our behavior for the better, and how we can make lasting changes in our lives.It's not easy to change our habits, but behavioral science offers us a roadmap for success. With enough patience and effort, we can overcome any obstacle and achieve our goals. So if you're struggling with a chronic illness, don't give up hope. There is help available, and with the right tools and support, you can succeed.Today my guest is Johannes Boshkow. Johannes always had a fascination with the way things worked - how molecules interact to create physical and chemical phenomena. This curiosity led him to study chemistry at some of the world's most renowned universities: ETH Zurich in Switzerland and Harvard University in the US.After completing his doctorate, He then joined the business development team at Observia in 2020 where he works on bringing innovative patient support to markets worldwide. He is fascinated by the ways that technology can improve people's lives, and he loves working at Observia because it combines his passion for life sciences with his interest in cutting-edge technology.Find Johannes on LinkedIn: https://www.linkedin.com/in/johannesboshkow/

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Guillermo Garcia-Manero, MD; Gail J. Roboz, MD - The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 20, 2022 64:16


Go online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists' case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today! Upon completion of this activity, participants should be better able to: Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS; Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS; Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS; Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

OffScrip with Matthew Zachary
[THROWBACK] The Heart of Healthcare with Mark Cuban

OffScrip with Matthew Zachary

Play Episode Listen Later Oct 20, 2022 25:12


Today we're dropping a very special throwback to a bonus episode of Out of Patients. Out of Patients is just one of many shows on the OffScrip Health network – and we want to make sure all of our excellent podcasts are on your radar!The Heart of Healthcare is a show that explores the social determinants of health, including our food system, housing, climate change, and more. It's hosted by long-time healthcare advocate Halle Tecco. Halle recently had the opportunity to welcome Mark Cuban to the show. The two hit it off and talked about the soaring costs of prescription drugs and his new venture – Mark Cuban Cost Plus Drug Company. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Mix Tape by Mix Talent
The Mix Tape | Reversing Chronic Disease: AndHealth's Mission to Improve Patient Outcomes and Reduce Healthcare Costs | Season 3 Episode 04

The Mix Tape by Mix Talent

Play Episode Listen Later Oct 19, 2022 49:57


In the US, a majority of people only see a doctor for a yearly check up. How do you address chronic medical conditions with such a "one and done" mindset? Erica Conroy and her work with AndHealth tackles that exact struggle. Mix Talent's KC McAllister sits down with Conroy on this week's episode. Conroy is the Senior Vice President of Employer Partnership at AndHealth, the leading digital health solution for autoimmune diseases and migraine. Employers use AndHealth's disease reversal programs to unlock employee engagement and productivity while reducing healthcare costs.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Javier Cortes, MD, PhD - SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes With Novel ER-Targeting Therapies

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Oct 19, 2022 14:51


Go online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improved outcomes in these patients, but most still develop endocrine resistance. ESR1 gene mutations, somatic alterations, microenvironmental factors, and epigenetic changes have all been implicated as underlying mechanisms promoting resistance. Novel ER-targeting agents such as oral selective estrogen receptor degraders (SERDs) are showing therapeutic promise in the face of ET resistance. In addition, other agents are being evaluated in ER+ disease, including selective estrogen receptor modifiers (SERMs), SERM/SERD hybrids, selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeras (PROTACs), and others.This PeerView educational activity, based on a recent live symposium, highlights and analyzes the latest evidence and advances in the treatment of ER+/HER2- breast cancer, focusing on the expanding evidence base supporting the use of novel ER-targeted agents such as oral SERDs as a new standard of care in pretreated ER+/HER2- breast cancer. Practical guidance is also provided on how to apply the latest evidence to practice, optimize the use of these agents, and individualize treatment plans that take into account key data, patient- and tumor-related factors, and the specific needs and preferences of each patient. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including novel oral SERDs and other ER-targeting therapies, and their evolving role in clinical practice; Develop individualized treatment plans for patients with previously treated ER+/HER2- breast cancer that take into account the latest treatment options and all the relevant treatment-, tumor-, and patient-related factors; Integrate a team-based, collaborative, coordinated, and patient-centered approach to select appropriate candidates for SERDs and other new therapies for ER+/HER2- breast cancer, provide essential patient education, and ensure optimal delivery of therapy

OffScrip with Matthew Zachary
Why Clinical Trial Enrollment Sucks

OffScrip with Matthew Zachary

Play Episode Listen Later Oct 18, 2022 33:36


My guest today is Dr. Selin Kurnaz, Founder and CEO of Massive Bio, a company that is as impressive as it sounds. Its mission is to solve one of the single most critical scathing holes in healthcare: the "last mile" of clinical trial enrollment. What does that mean? You'll find out during our conversation, and rightfully so; the explanation will further deepen your pre-existing disdain for "the system." Selin is a no-BS serial entrepreneur who defines herself as a "non-status-quo businesswoman." whose sole purpose is to ensure every cancer patient gets access to a clinical trial; because only 20% of all patients that qualify for a clinical trial never actually fully enroll in that trial. And that is not OK. All that and more on the show today, let's get started.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.